Jennifer H Lai1, Gavin Park2, Lauren B Gerson3. 1. Department of Gastroenterology, California Pacific Medical Center, San Francisco, California, USA. 2. Department of Internal Medicine, California Pacific Medical Center, San Francisco, California, USA. 3. Department of Gastroenterology, California Pacific Medical Center, San Francisco, California, USA; Department of Medicine, University of California, San Francisco, California, USA.
Abstract
BACKGROUND: The literature to date has suggested a potential increase in colorectal cancer (CRC) among patients with breast cancer. METHODS: We performed a systematic review of the literature and included 37 retrospective cohort studies and 8 case-control studies. The primary aim was to determine the prevalence of CRC. Secondary aims included analysis of adenomatous polyps and analysis of CRC prevalence by age. We calculated pooled prevalence rates and odds ratios (ORs) using random effects models with 95% confidence intervals (CI). RESULTS: We identified 1,055,917 individuals with breast cancer among whom 9097 cases of CRC were detected. The pooled event rate for CRC was 0.7% (95% CI, 0.6%-0.9%; I2=97%). Four case-control studies reported prevalence of CRC (N=17,873 patients with breast cancer and 70,366 controls), including 46 cases of CRC in the patients with breast cancer, and 272 CRC in the controls (OR, 1.2; 95% CI, 0.4%-3.7%; P = .7). Six studies reported prevalence of advanced adenomas in patients with breast cancer (N=1087) compared with controls (N=1356) with 62 cases of advanced adenomas in patients compared with 47 in the controls (OR, 1.5; 95% CI, 0.97-2.2; P = .07). In patients with breast cancer <50 years old (4 studies, N=64,706), the pooled OR was increased (OR, 2.5; 95% CI, 1.7-3.5; P =.001). In 3 studies of women <45 years old (N=92,594), the risk was increased (OR, 2.3; 95% CI, 1.7-2.6; P < .001). CONCLUSIONS: Patients with breast cancer should not undergo CRC screening at intervals different from the general population. In patients with breast cancer <50 years old, CRC screening should be considered at age 45 years.
BACKGROUND: The literature to date has suggested a potential increase in colorectal cancer (CRC) among patients with breast cancer. METHODS: We performed a systematic review of the literature and included 37 retrospective cohort studies and 8 case-control studies. The primary aim was to determine the prevalence of CRC. Secondary aims included analysis of adenomatous polyps and analysis of CRC prevalence by age. We calculated pooled prevalence rates and odds ratios (ORs) using random effects models with 95% confidence intervals (CI). RESULTS: We identified 1,055,917 individuals with breast cancer among whom 9097 cases of CRC were detected. The pooled event rate for CRC was 0.7% (95% CI, 0.6%-0.9%; I2=97%). Four case-control studies reported prevalence of CRC (N=17,873 patients with breast cancer and 70,366 controls), including 46 cases of CRC in the patients with breast cancer, and 272 CRC in the controls (OR, 1.2; 95% CI, 0.4%-3.7%; P = .7). Six studies reported prevalence of advanced adenomas in patients with breast cancer (N=1087) compared with controls (N=1356) with 62 cases of advanced adenomas in patients compared with 47 in the controls (OR, 1.5; 95% CI, 0.97-2.2; P = .07). In patients with breast cancer <50 years old (4 studies, N=64,706), the pooled OR was increased (OR, 2.5; 95% CI, 1.7-3.5; P =.001). In 3 studies of women <45 years old (N=92,594), the risk was increased (OR, 2.3; 95% CI, 1.7-2.6; P < .001). CONCLUSIONS:Patients with breast cancer should not undergo CRC screening at intervals different from the general population. In patients with breast cancer <50 years old, CRC screening should be considered at age 45 years.
Authors: Hamzah Abu-Sbeih; Faisal S Ali; Phillip S Ge; Carlos H Barcenas; Phillip Lum; Wei Qiao; Robert S Bresalier; Manoop S Bhutani; Gottumukkala S Raju; Yinghong Wang Journal: Ann Gastroenterol Date: 2019-05-20
Authors: Yiqing Huang; Yu Yang Soon; Lay Poh Ngo; Ying Hui Dina Ee; Bee Choo Tai; Hung Chew Wong; Soo Chin Lee Journal: Asian Pac J Cancer Prev Date: 2019-06-01
Authors: Hamzah Abu-Sbeih; Faisal S Ali; Wei Qiao; Phillip Lum; Mehnaz A Shafi; Robert S Bresalier; Ernest Hawk; Gottumukkala S Raju; Yinghong Wang Journal: J Cancer Date: 2020-03-04 Impact factor: 4.207
Authors: Beth A Glenn; Narissa J Nonzee; Ann S Hamilton; Lina Tieu; Annette E Maxwell; Catherine M Crespi; L Cindy Chang; Dennis Deapen; Roshan Bastani Journal: J Cancer Surviv Date: 2020-08-14 Impact factor: 4.442